SANJIVIN.BO · BSE
SANJIVANI PARANTERAL LTD.
₹172.9
+0.88% (+₹1.5)
Prev. close
₹171.4
Volume
4,651
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About SANJIVANI PARANTERAL LTD.
Sanjivani Paranteral Limited operates as a pharmaceutical company in India. The company manufactures pharmaceutical products in the form of oral solids, small volume parenteral, and sterile powder formulations for various therapeutic areas, including central nervous system, cardiovascular system, antibiotics, gastroenterological, anti-diabetics, and anti-allergic. It also offers soft gels, such as multivitamins; topicals comprising corticosteroids, antiseptics, NSAIDs, anti-fungal, and anti-bacterial; nasal sprays; liquid and dry powder injections covering antibiotics, anti-emetic, NSAID and analgesic, antimalarial, and proton pump inhibitor and H2 receptor antagonist; capsules and tablets, including antibiotic, antifungal, anticonvulsant, multivitamins, and NSAID and analgesic; dry syrups; and ear/eye drops. In addition, the company exports its products. Sanjivani Paranteral Limited was incorporated in 1994 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Ashwani Anamisharan Khemka B.A
Headquarters
Mumbai
Employees
43
Website
sanjivani.co.inExchange
View on BSE ↗Key stats
Market cap
₹212.40 Cr
P/E ratio (TTM)
28.5
Dividend yield
0.28%
EPS (TTM)
₹6.06
Beta (1Y · daily vs NIFTY 50)
1.05
Beta (5Y · monthly vs NIFTY 50)
1.31
Shares float
59.30 L
EPS · quarter ended Jun 2026
₹2.03
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.7% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹25.10 Cr | ₹30.61 Cr | ₹35.24 Cr | ₹53.69 Cr | ₹69.56 Cr | ₹68.27 Cr | |
| EBITDA | ₹2.40 Cr | ₹5.97 Cr | ₹6.06 Cr | ₹8.63 Cr | ₹11.38 Cr | ₹11.16 Cr |
| ₹1.42 Cr | ₹4.85 Cr | ₹4.51 Cr | ₹6.17 Cr | ₹8.10 Cr | ₹6.79 Cr | |
| Diluted EPS | ₹1.67 | ₹4.85 | ₹4.51 | ₹5.28 | ₹6.66 | ₹5.49 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹21.01 Cr | ₹43.41 Cr | ₹78.20 Cr | ₹87.97 Cr | |
| — | — | ₹2.49 Cr | ₹96.91 L | ₹8.14 Cr | ₹14.28 Cr | |
| Stockholders' equity | — | — | ₹-3.07 Cr | ₹27.90 Cr | ₹38.00 Cr | ₹48.25 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹4.68 Cr | ₹-10.70 Cr | ₹12.40 Cr | ₹-11.39 L | |
| Investing cash flow | — | — | ₹-99.11 L | ₹-12.21 Cr | ₹-21.91 Cr | ₹-9.97 Cr |
| — | — | ₹-3.73 Cr | ₹23.16 Cr | ₹10.46 Cr | ₹9.84 Cr | |
| Capital expenditure | — | — | ₹-1.10 Cr | ₹-3.30 Cr | ₹-30.35 Cr | ₹-10.18 Cr |
| End cash position | — | — | ₹30.25 L | ₹54.08 L | ₹1.49 Cr | ₹1.24 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| SANJIVANI PARANTERAL LTD. | ₹214.36 Cr | ₹174.5 | 28.8 | 4.44 | 14.1% | 0.30 | -1.9% | -28.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 26
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Sanjivani Paranteral Limited Reports Earnings Results for the First Quarter Ended June 30, 2026
marketscreener.com · 1 month ago